Anthera Expands European Screening Sites for Clinical Study of Sollpura

Anthera (NASDAQ:ANTH) started screening in Europe for the RESULT phase 3 clinical study of Sollpura treating exocrine pancreatic insufficiency due to cystic fibrosis.
As quoted in the press release:

International enrollment is expected to provide topline data at the end of 2017 or early 2018.
“We are very much looking forward to supporting Anthera in their efforts to bring this novel, biotech-derived pancreatic enzyme replacement therapy to patients,” shared Dr. Fernando Casals Seoane (Hospital Universitario de La Princesa, Madrid, Spain).  Dr. Amparo Solé Jover (Hospital La Fe de Valencia, Valencia, Spain) further added, “We have been involved with the Sollpura program since Anthera initiated its clinical development with the SOLUTION study and we are pleased that the RESULT study is now underway in Europe.”

Click here to read the full press release.

Source: globenewswire.com